June was packed with exciting events and we had a great time exhibiting at ADH annual meeting in Göttingen as well as IFPA conference in Stockholm.

“We need this test in our lab!” – it’s hard to imagine a better welcome from a visitor to our booth. Even though we were serving a niche with dermatopathology at the 107th Annual Meeting of the German Society of Pathology (DGP), we were even more pleased about the enthusiasm shown by our booth visitors.

By participating in several conferences and trade shows in the US – most recently at the ISDP meeting in San Diego – Dermagnostix has already been able to show that the interest in PsorX is high and the feedback is consistently positive. In 2024, the focus will shift even more to business development in the USA. The

Dermagnostix took part in the 5th DIAD-DIAL conference from 3-5 November in Dubai.

The dermatopathology of tomorrow – Dermagnostix at the ADH 2023 in Lübeck

Dermagnostix participated in the National Eczema Association Expo in Orlando, Florida, June 23-25, 2023.

Molecular Diagnostics for Dermatology Drug Development

“A recently presented poster session from RAD 2023 evaluated a gene expression based molecular test’s differential diagnosis of psoriasis and eczema.

Dermagnostix is featured in the journal series ‘Karger Kompass’ aimed at clinicians and specialists in private practice with a focus on young, committed physicians with four specialist target groups of pneumologists, dermatologists, oncologists and ophthalmologists.

Dermagnostix announces mid-term analysis of ongoing 3-year clinical utility study on PsorX classifier sponsored by the DGUV (German Accident Insurance Company) was presented at ADF.